Binimetinib for the treatment of NRAS-mutant melanoma.

Abstract excerpt

INTRODUCTION: Activating NRAS mutations occur in approximately 15-20% of melanomas and are the second most common oncogenic driver mutation in this disease, after BRAF mutations. There is an unmet medical need for new targeted therapy opportunities in metastatic patients whose tumors harbor an NRAS mutation. Binimetinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, has shown clinical activity in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Benzimidazoles
• Share to Disease-Free Survival
• Share to GTP Phosphohydrolases